Health & Fit Pfizer, BioNTech surge after the US government orders 100 million doses of COVID-19 vaccine
Coronavirus vaccines: 'Encouraging' early data for some, a trial delay for another and more research ahead
Scientists around the world are racing to develop Covid-19 vaccines and there's news almost daily about steps forward -- this week, there was "encouraging" preliminary data for some vaccine candidates and word from top health officials that the United States could be on track to have a vaccine by the end of the year. © BioNTech A biotech company in Germany has begun its first human trials of a potential Covid-19 vaccine. According to the World Health Organization, there are 18 candidate vaccines in clinical evaluation globally.
- Pfizer and BioNTech that the US government has placed an initial order for 100 million doses of its coronavirus vaccine.
- Shares of jumped as much as 6% in premarket trading Wednesday. Shares of rose nearly 8% at the same time.
- Americans will receive the vaccine for free,
- and on Markets Insider.
and , a German biotech firm, that the US government has placed an initial order for 100 million doses of its coronavirus vaccine.
Doctors Break Down the Long Road Ahead to Getting a Viable COVID-19 Vaccine
Adrian Hill, the lead researcher in Oxford University's vaccine test on humans, shares encouraging results from their testing, and says they are still hoping to have a Covid-19 vaccine by the end of the year.
Shares of both companies surged in premarket trading Wednesday. Pfizer jumped as much as 6%, while BioNTech rose nearly 8%.
The US government will pay $1.95 billion for the doses when they're manufactured and Pfizer obtains approval or emergency use authorization from the Food and Drug Administration. The government can also acquire up to 500 million additional doses of the vaccine under the agreement.
The agreement with Pfizer and BioNTech is part of the US government's Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021.
Don't hold your breath for a coronavirus vaccine. Here are the 7 biggest challenges we still need to overcome.
Creating a coronavirus vaccine is just half the battle. The exit plan for this pandemic, on the other hand, is uncharted territory.
"Expanding Operation Warp Speed's diverse portfolio by adding a vaccine from Pfizer and BioNTech increases the odds that we will have a safe, effective vaccine as soon as the end of this year," said Health and Human Services Secretary Alex Azar
Americans will receive the vaccine for free,
Pfizer and BioNTech remain on track to begin the next phase of the potential coronavirus vaccine's safety and efficacy trial later this month, and will seek a regulatory review as early as October 2020.
The companies plan to manufacture up to 100 million doses globally by the end of the year, and increase output to 1.3 billion doses by the end of 2021.
Video: Pfizer-BioNTech vaccine shows promise (Reuters)
How anti-vaxxers are thinking about a Covid-19 vaccine
Vaccine refusal was growing before the pandemic. Then came Covid-19.These words were offered by Barbara Loe Fisher, founder of the largest national organization in the US opposed to vaccine requirements in 2019, long before Americans had imagined the Covid-19 outbreak. Speaking at an event organized by “Crazy Mothers,” a group whose stated goals include bringing attention to injuries caused by childhood vaccines and empowering mothers to make informed health care decisions, Fisher’s comments were meant to condemn state laws that require childhood vaccinations for school attendance and recent state efforts to tighten enforcement of those requirements.
BioNTech buys new plant to boost production of potential coronavirus vaccine .
German pharmaceutical company BioNTech, which is currently developing a possible vaccine against the novel coronavirus together with US drug giant Pfizer, announced Thursday it was buying a new production plant in order drastically to increase its production capacities. © Thomas Lohnes/Getty Images MAINZ, GERMANY - APRIL 22: The headquarters of German immunotherapy company BioNTech stands on April 22, 2020 in Mainz, Germany. BioNTech and U.S. pharmaceutical giant Pfizer announced today that German authorities have granted them approval to begin clinical trials for BioNTech's BNT162, a possible vaccine against Covid-19.